Kura Oncology formed a wholly owned subsidiary, Caspian Therapeutics, to develop next-generation menin inhibitors for diabetes and cardiometabolic diseases. On September 8, 2026, Caspian completed a private financing of $50.0 million in Series A preferred stock, with Kura Oncology investing $4.3 million. Following the transaction, Kura holds approximately 49.2% of Caspian's outstanding capital stock. The Company also entered into a Contribution and License Agreement to transfer rights for compounds like KO-7246 to Caspian in exchange for common stock and up to $1.5 million in cost reimbursement. Additionally, an intercompany services agreement was executed for research and administrative support. Kura Oncology operates in the biotechnology industry, focusing on the discovery and development of targeted therapies for cancer.

Kura Oncology appointed Jennifer Fulk as its new Chief Financial Officer and principal accounting officer effective September 8, 2026. She replaces Troy E. Wilson in the CFO role and Thomas Doyle as principal accounting officer. Her compensation package includes a $550,000 annual base salary, an option to purchase 450,000 shares, and restricted stock units covering 173,438 shares. The filing details specific severance terms tied to potential corporate transactions. Kura Oncology operates in the biotechnology industry, focusing on the discovery and development of targeted therapies for cancer.

Kura Oncology, Inc. reported second quarter 2026 financial results on August 12, 2026. Net product revenue from KOMZIFTI (ziftomenib) reached $9.1 million, a 57% increase from the first quarter, driven by approximately 115 new patient starts and over 250 total prescriptions. The company reported a net loss of $68.3 million compared to $66.1 million in the prior year period. As of June 30, 2026, Kura held $519.0 million in cash, cash equivalents, and short-term investments, supplemented by $180 million in anticipated collaboration payments from Kyowa Kirin. The company provided clinical updates on ziftomenib's frontline AML potential and darlifarnib's activity in solid tumors. Kura Oncology is a biopharmaceutical company focused on precision medicines for cancer.

Kura Oncology, Inc. entered into amended and restated executive employment agreements with Chairman, President and CEO Troy E. Wilson, CCO Brian Powl, and COO Kathleen Ford to modify severance provisions. Under the new terms, executives receive enhanced double-trigger change-in-control benefits if terminated without cause or for good reason within 59 days prior to or 18 months after a corporate transaction. Dr. Wilson is entitled to 24 months of base salary and 200% of target bonus, while Messrs. Powl and Ms. Ford receive 18 months of base salary and 150% of target bonus. All agreements include full acceleration of equity vesting and extended COBRA coverage. Kura Oncology operates in the biotechnology industry, focusing on the discovery and development of small molecule therapies for cancer.